Return to Listing

19 result(s) for Phase I Clinical Trials

PI Name Protocol # Title
Rebecca Silbermann IRB00008820 Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
Richard Maziarz IRB00009375 A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT
Matthew Taylor STUDY00015206 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Rachel Cook STUDY00015214 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Matthew Taylor STUDY00015678 A Phase 1a/1b Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers
Matthew Taylor STUDY00016198 A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
Tomasz Beer STUDY00016294 Phase 1b Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide or Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-002)
Matthew Taylor STUDY00016676 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Matthew Taylor STUDY00016702 A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors
Matthew Taylor STUDY00017674 A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Matthew Taylor STUDY00018111 Modular phase 2 study to link combination immune-therapy to patients with advanced solid and hematologic malignancies Module 9: PDR001 plus LAG525 for patients with advanced solid and hematologic malignancies
Matthew Taylor STUDY00018118 A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3011 IN PATIENTS WITH ADVANCED SOLID TUMORS
Matthew Taylor STUDY00018164 A PHASE 1/2 STUDY OF ORAL LOXO-292 IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001)
Matthew Taylor STUDY00018303 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Matthew Taylor STUDY00018498 A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 IN PATIENTS WITH ADVANCED SOLID TUMORS
Matthew Taylor STUDY00018788 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Matthew Taylor STUDY00019388 A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Matthew Taylor STUDY00019390 A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose- Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
Matthew Taylor STUDY00019479 An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080